Pulmonary-Allergy Drugs Advisory Committee
Committee Meeting on June 23, 2011, from 8:30 a.m. to 5 p.m.
Agenda: On June 23, 2011, the committee will discuss the new drug application (NDA) 22150, icatibant solution for injection (proposed trade name Firazyr), Shire Human Genetic Therapies, for the proposed indication of treatment of acute attacks of hereditary angioedema.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment